Clinical Trials Logo

Cervical Intraepithelial Neoplasia clinical trials

View clinical trials related to Cervical Intraepithelial Neoplasia.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05595252 Enrolling by invitation - Clinical trials for Cervical Intraepithelial Neoplasia

Retrospective Study on the Evolution of CIN 1 to 3 in Per and Postpartum in Nancy From 2014 to 2022

Start date: January 1, 2014
Phase:
Study type: Observational

In France, the screening rate for cervical cancer remains too low. Screening is simple and non-invasive. Pregnant patients are most of the time young and are part of the target population for screening, and for many women, it is the first encounter with a gynecologist. The cervical smear is therefore an important step of the first consultation during pregnancy In the case of pathological results, colposcopies with biopsies are performed, frequently finding CIN 1 to 3. (cervical intraepithelial neoplasia) These CIN lesions evolve slowly and most of the time, treatment can be withheld until the end of the pregnancy. Several studies suggest a higher regression rate in pregnant patients. Our study will evaluate the rate of regression, progression or persistence of these lesions in per and post partum patients in Nancy, between 2014 and 2022. To obtain our results, we will compare the results of per and post partum biopsies in each patient. In a second step, we will study the risk factors of aggravation or on the contrary the protective factors, allowing a faster regression of the lesions

NCT ID: NCT04755517 Enrolling by invitation - Clinical trials for Cervical Intraepithelial Neoplasia Grade 2/3

Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)

HPV400
Start date: June 9, 2020
Phase: N/A
Study type: Interventional

To identify: 1) Whether being informed infrequently results about screening is at least as a) safe and b) accurate as frequently obtaining all information from (the present combination of opportunistic/organized) cervical screening by comparing regimen results of two screening visits at the ages of 25 and 28 years (Arm A1) vs. results of one screening visit at the age of 28 years (Arm A2) in unvaccinated herd effect protected women. Unvaccinated, frequently screened women, who are not under herd effect protection will be controls (C).

NCT ID: NCT04266093 Enrolling by invitation - Clinical trials for Cervical Intraepithelial Neoplasia

Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies

Start date: May 8, 2020
Phase:
Study type: Observational

Background: Gene therapy is closely followed by the U.S. Food and Drug Administration (FDA). The FDA requires researchers to conduct long-term follow-up of people who have had the treatment. This study collects data on people who have had gene therapy and sends it to the FDA. The data does not include participants names. Objective: To contact current or past participants of gene therapy protocols at least once a year for up to 15 years to ensure they have not had any harmful side effects. Eligibility: People aged 18 and older who have had gene therapy in a National Cancer Institute study Design: Participants will give their address and telephone number. They will also give and the address and phone number of 1 or 2 other people who will know where they are. For the first year after gene therapy, participants will give blood samples 3 times (at 3, 6, and 12 months). For the next 4 years, they may have a physical exam and laboratory tests with a home physician. They will get a kit to mail in blood samples. Or they can visit the NIH Clinical Center. They will be asked if they have had any signs of neurological, autoimmune, or blood disorders, or any new cancers. For years 6 to 15, participants will be contacted yearly via phone or email and asked questions about their health. They may give blood samples. When the participant dies, if researchers think the death was caused by gene therapy, they will ask the participant s family to allow an autopsy. ...

NCT ID: NCT01371695 Enrolling by invitation - Cervical Cancer Clinical Trials

Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer

Start date: May 2011
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether Insulin-like Growth Factor II is elevated sufficiently to detect Cervical Intraepithelial Neoplasia II (CIN II), Cervical Intraepithelial Neoplasia III (CIN III), and cervical cancer.

NCT ID: NCT01095198 Enrolling by invitation - Clinical trials for Cervical Intraepithelial Neoplasia

Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)

Start date: April 2010
Phase: Phase 2/Phase 3
Study type: Interventional

Up to 30% of Canadian women do not participate in Pap smear screening for cervical cancer prevention despite many being members of family practices and having access to family physicians. One reason is reluctance to undergo pelvic examination. The investigators purpose is to determine whether the offer of vaginal self sample collection for oncogenic human papillomavirus (HPV) testing increases participation in cervical cancer screening compared to repeat reminder for Pap smear testing among female family practice members who have not previously responded to invitations for Pap testing.

NCT ID: NCT00842738 Enrolling by invitation - Cervical Dysplasia Clinical Trials

Can Alternative Treatment Have an Impact on Cervical Dysplasia?

Start date: March 2009
Phase: Phase 4
Study type: Interventional

In this study two questions will be answered: - can mindfulness meditation help cell-changed on the cervix to disappear? - can mindfulness meditation lower the psychological distress when women have abnormal cervical cancer screening results?